Coherus BioSciences (CHRS) Tops Q3 EPS by 15c

Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Oppenheimer Reiterates Outperform Rating on salesforce.com (CRM)
• Veeva Systems (VEEV) PT Raised to $276 at Guggenheim